"I am pleased to have this patent issued," stated
Cathepsins have been validated as an important enzymatic class to target in drug discovery research, and eleven cysteine protease cathepsin enzymes have been identified to date in humans, with different structures and functions. Cathepsin L has a function in the growth and metastasis of primary tumors and has been implicated in diabetes, immunological responses, degradation of the articular cartilage matrix, and other pathological processes, including osteoporosis and rheumatoid arthritis. Inhibition of cathepsin L has also been shown to block Severe Acute Respiratory Syndrome (SARS) and Ebola pseudotype virus infection. Cathepsin K plays a role in bone resorption and has implications in osteoporosis.
At Mateon, we believe that we can significantly improve cancer therapy by employing these two complementary approaches simultaneously. When utilized this way, VDAs obstruct existing blood vessels in the tumor leading to significant central tumor cell death while AAs prevent the formation of new tumor blood vessels.
Mateon is committed to leveraging our intellectual property and the product development expertise of our highly skilled management team to enable VTT to realize its true potential and to bring much-needed new therapies to cancer patients worldwide.
Safe Harbor Statement
This news release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Any or all of the forward-looking statements in this press release, which include the timing of advancement, outcomes, data and regulatory guidance relative to our clinical programs and achievement of our business and financing objectives may turn out to be wrong. Forward-looking statements can be affected by inaccurate assumptions Mateon might make or by known or unknown risks and uncertainties, including, but not limited to, the inherent risks of drug development, manufacturing and regulatory review, and the availability of additional financing to pursue and continue development of our programs. Additional information concerning factors that could cause actual results to materially differ from those in the forward-looking statements is contained in Mateon's reports to the
Investors: email@example.com 650-635-7000 Media:
JPA Health Communications Nic DiBellanic@jpa.com 617-945-5183
News Provided by Acquire Media